MedTrace Logo

A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF

NCT05409547 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-06-16

No results posted yet for this study

Summary

Have a comparison between pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) and recombinant human granulocyte-colony stimulating factor (rhG-CSF) for difference in efficacy of hematopoietic reconstruction after autologous peripheral blood stem cell mobilization (PBSCM) and autologous peripheral blood stem cell transplantation (APBSCT).

Primary purpose:

Compare the difference between PEG-rhG-CSF and G-CSF in PBSCM.

Secondary purpose:

Compare the difference between PEG-rhG-CSF and G-CSF in APBSCT.

Conditions

  • Granulocyte Colony-stimulating Factor
  • Stem Cell Mobilization

Interventions

DRUG

PEG-rhG-CSF

PEG-rhG-CSF 6 mg/d (single dose) will be given on the second day after chemotherapy.

Sponsors & Collaborators

  • Ning Huang

    lead OTHER

Principal Investigators

  • ning huang, Professor · professor

  • kehong bi, Professor · professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2025-04-30
Completion
2025-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05409547 on ClinicalTrials.gov